- Home
- / LakeShore Biopharma
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
LakeShore Biopharma financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Stock Price
$0.5
2024-07-26
Market Capitalization
$192.1 M
2024-07-26
Revenue
¥615 M
FY, 2025
CreditSafe Score
?
Score changed on Jun 09, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| CNY | FY, 2021 | FY, 2022 | FY, 2023 | FY, 2024 | FY, 2025 |
|---|---|---|---|---|---|
| Revenue | 257.0M | 503.0M | 687.2M | 573.4M | 615.0M |
| Cost of goods sold | 31.8M | 85.9M | 116.7M | 75.5M | 71.1M |
| Gross profit | 225.3M | 417.0M | 570.5M | 497.9M | 543.8M |
| Gross profit margin, % | 87.6% | 82.9% | 83.0% | 86.8% | 88.4% |
| Operating expense total | 323.2M | 504.8M | 673.2M | 744.1M | 556.8M |
| Depreciation and amortization | 27.9M | 31.2M | 36.7M | 199.6M | 73.4M |
| EBITDA | (97.9M) | (87.8M) | (102.7M) | (246.2M) | (12.9M) |
| EBITDA margin, % | -38.1% | -17.5% | -14.9% | -42.9% | -2.1% |
| EBIT | (144.7M) | (98.3M) | (113.5M) | (415.3M) | (86.3M) |
| EBIT margin, % | -56.3% | -19.6% | -16.5% | -72.4% | -14.0% |
| Interest expense | 29.7M | 2.7M | 30.9M | 44.3M | 15.7M |
| Pre tax profit | (174.4M) | (101.1M) | (144.3M) | (455.2M) | (100.9M) |
| Income tax expense | 17.5M | 4.9M | 1.1M | (21.7M) | (947.0K) |
| Net Income | (191.8M) | (106.0M) | (145.5M) | (433.5M) | (100.0M) |